← Back to guidelines
Oncology26 papers

Infiltrating lobular carcinoma of breast

Last edited: 4/10/2026

Overview

Infiltrating lobular carcinoma (ILC) is a subtype of breast cancer characterized by a distinct pattern of tumor cell infiltration. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer, including ILC, is gaining momentum as a prognostic and potentially predictive biomarker 1.

Diagnosis

  • Morphological evaluation of TILs can be performed on hematoxylin and eosin (H&E)-stained tumor sections 1.
  • A standardized methodology for evaluating TILs is needed for integration into standard histopathological practice and clinical trials 1.
  • Management

  • TILs have shown prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing breast cancer 1.
  • Key Recommendations

  • The extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of H&E-stained tumor sections 1. (Evidence: Moderate)
  • A standardized methodology for evaluating TILs is required as a prerequisite for integrating this parameter into standard histopathological practice, research settings, and clinical trials 1. (Evidence: Moderate)
  • The methodology provided offers a pragmatic starting point to improve consistency and reproducibility in the measurement of TILs for future studies 1. (Evidence: Expert opinion)
  • References

    1 Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G et al.. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of oncology : official journal of the European Society for Medical Oncology 2015. link

    Original source

    1. [1]
      The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G et al. Annals of oncology : official journal of the European Society for Medical Oncology (2015)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG